Pharmaceutically active compound
CA 2416608 A1 · Owner: Norgine Europe Bv · Inventors: Mills, Charles Oswald
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
A liver-targeting active compound has the general formula (I):- wherein A is .alpha.-OH or .beta.-OH, B is .alpha.-H or .beta.-H C is -H, .alpha.-OH or , .beta.-OH, or B and C together form a double bond D is -H, .alpha.-OH or , .beta.-OH, E is -H .alpha.-OH or .beta.-OH, -G-is a side chain moiety -NH-J , is selected from (i) a residue of an amino group-containing active compound wherein said -NH- group is provided by said amino group of the active compound, and (ii) a residue of an active compound to which an amino group has been added wherein said -NH- group is provided by said added amino group; each of X and Y independently represents a single bond -(CH2)z-(where z is 1 to , 8), …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed July 19, 2001. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended July 19, 2021.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by July 19, 2023.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.